ADC Therapeutics Raises $200M to Fund Two Lead Programs in Non-Hodgkin’s Lymphoma
News
ADC Therapeutics, a company specializing in the development of antibody drug conjugates (ADCs) for several cancer indications, has raised $200 million through a private placement. The financing will be used ... Read more